Idera Pharmaceuticals Inc (NASDAQ:IDRA) announce plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. Idera Pharmaceuticals Inc (NASDAQ:IDRA) stock performance was 1.23% in last session and finished the day at $ 2.47. Traded volume was 2,242,021 shares in the last session and the average volume of the stock remained 3.52 million shares. The beta of the stock remained 2.46. Idera Pharmaceuticals Inc (NASDAQ:IDRA) insider ownership is 0.60%.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) slipped -6.85%, the stock was spiking up in the morning after it announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 patients with irritable bowel syndrome with constipation. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) rose 0.80% to $ 3.78 yesterday on volume of 2,365,891 shares. The intra-day range of the stock was $ 3.39 – 3.82. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has a market capitalization of $ 353.69 million.

Amarin Co. plc (ADR) (NASDAQ:AMRN) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.18) by $0.02. Amarin Corporation plc (ADR) (NASDAQ:AMRN)’s stock on May 9, 2014 reported a decrease of -3.21% to the closing price of $ 1.51. Its fifty two weeks range is $ 1.36 – 7.98. The total market capitalization recorded $ 261.06 million. The overall volume in the last trading session was 2,373,845 shares. In its share capital, Amarin Corporation plc (ADR) (NASDAQ:AMRN) has 172.87 million outstanding shares.

Depomed Inc (NASDAQ:DEPO) announced its earnings results on Thursday. The company reported ($0.01) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.10 by $0.11, Analyst Ratings News reports.On Friday, shares of Depomed Inc (NASDAQ:DEPO) advanced/dropped 768% to close the day at $888. Company return on investment (ROI) is 56.677% and its monthly performance is recorded as 60.88%. Depomed Inc (NASDAQ:DEPO) quarterly revenue growth is 878%.